Policy / Alpha Vantage News Sentiment

Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares

Werewolf Therapeutics director Luke Evnin's associated funds sold a total of 143,199 shares of Common Stock in open-market transactions on July 6 and July 7, 2026. These sales, executed under a pre-established Rule 10b5-1 trading plan, resulted in a weighted average price of $0.32 and $0.31 per share respectively. Following these transactions, the MPM-affiliated entities involved no longer hold shares of Werewolf Therapeutics.